• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Emergency

Meningococcal B vaccine induces protective antibody response in adolescents and young adults

byShani ChibberandDayton McMillan
December 15, 2017
in Emergency, Infectious Disease, Pediatrics, Public Health
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Healthy adolescents and young adults treated with the Neisseria meningitidis vaccine MenB-FHbp had increased bactericidal antibody responses (hSBA titer) compared to those treated with control vaccines.

2. More localized injection-site reactions occurred among patients treated with the meningococcal B vaccine compared to control vaccines.

Evidence Rating Level: 2 (Good)

Study Rundown: Neisseria meningitidis infection remains a pervasive health concern for infants, adolescents, and young adults. Though validated capsular polysaccharide-based vaccines exist for common meningitis serogroups A, C, W and Y, vaccines for the invasive disease-causing meningitis serogroup B have only recently been introduced. This multicenter, phase 3 randomized control trial assessed the immunogenicity and safety profile of MenB-FHbp, a meningococcal B vaccine that contains surface-exposed factor H-binding protein in two separate cohorts of adolescents and young adults. The primary objective was evaluation of an observed immune response to 4 primary test strains of meningococcal B measured one month after participants’ 3rd vaccination dose. A broad immunogenic response was observed to the MenB-FHbp vaccine, evidenced by increased antibody titers, after the treatment period across all primary meningococcal B strains tested. From a safety standpoint, localized injection-site pain was noted as the most common adverse reaction in both meningococcal vaccine and control treated patients. This study demonstrates broad bactericidal response to various meningococcal B strains after vaccination, though clinical efficacy for reducing meningococcal disease will require further study.

Click to read the study, published in NEJM

Relevant Reading: Updated recommendations for use of menB-FHbp serogroup B meningococcal vaccine – advisory committee on immunization practices, 2016

In-Depth [randomized controlled trial]: This phase 3, observer-blinded, multicenter randomized control trial included 3596 and 3304 healthy adolescents (10-18 years old) and young adults (18-25), respectively. Adolescents were randomized to receive intramuscular injections of either MenB-FHbp or hepatitis A with saline. Young adults were randomized to receive either MenB-FHbp or saline. All participants received injections at timed intervals of 0, 2, and 6 months post-randomization. Of those randomized, 3272 (91.0%) adolescents and 2474 (74.9%) young adults completed the vaccination schedule. The primary endpoint was measured by determining the percent of participants who exhibited an increase in hSBA titer activity by at least a factor of 4 after their third vaccination. Adolescents in the meningococcal vaccine groups who met this criterion ranged from 78.8% to 90.2%, depending on the meningococcal B strain tested (A22, A56, B24, and B44). This percent ranged from 78.9% to 89.7% of young adults. By comparison, percentages in both control groups were noted to be 11.0% or less. Composite hSBA titer response were 82.7% in adolescents and 84.5% in young adults randomized to receive MenB-FHbp; the composite response was 7.4% or less in control groups. The overall frequency of adverse events was comparable between treatment and control groups for both trial cohorts. There were a total of 51 serious adverse events in the adolescent active-treatment arm compared to 22 in the adolescent control arm; none were deemed study-related. By comparison, there were 33 serious adverse events in the young adult active-treatment arm and 11 in the young adult control arm; 3 events or 1.3% of the active arm events were deemed vaccine-related.

RELATED REPORTS

Respiratory syncytial virus (RSV) vaccine produces transplacental neutralizing antibodies in pregnant women

Inactivated, adjuvant enterovirus 71 vaccine is safe and effective against fatal enterovirus infections in children aged 2-71 months

DNA-based vaccine, ZyCoV-D, is safe and efficacious against COVID-19 infection for patients aged 12 years and older

Image: PD

©2017 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: meningitisvaccine
Previous Post

Poverty, preterm birth demonstrate additive effect on cognition

Next Post

Ablation of refractory ventricular tachycardia with a novel, noninvasive radiation technique

RelatedReports

Clinical practice guidelines linked to improved bronchiolitis outcomes
Infectious Disease

Respiratory syncytial virus (RSV) vaccine produces transplacental neutralizing antibodies in pregnant women

May 13, 2022
Preterm infants responsive to PCV13 vaccine
Infectious Disease

Inactivated, adjuvant enterovirus 71 vaccine is safe and effective against fatal enterovirus infections in children aged 2-71 months

May 10, 2022
Compliance-linked incentives increase infant immunizations rates in rural India
Infectious Disease

DNA-based vaccine, ZyCoV-D, is safe and efficacious against COVID-19 infection for patients aged 12 years and older

April 12, 2022
Novel coronavirus identified from patients with pneumonia in Wuhan, China
Chronic Disease

AD26.COV2.S vaccine provides protection against Covid-19

March 7, 2022
Next Post
Long-term outcomes for off-pump and on-pump CABG are similar

Ablation of refractory ventricular tachycardia with a novel, noninvasive radiation technique

Significant percentage of pediatricians dismiss families who refuse vaccines

Mandated risk-benefit counseling decreases rate of vaccine exemptions

Ultrasound enhances gastrointestinal absorption of drugs at low frequencies

Household prescription opioid exposure linked to small increased risk of opioid initiation

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Wellness Check: Mental Health
  • #VisualAbstract: Addition of elotuzumab to lenalidomide and dexamethasone did not significantly improve survival outcomes in newly diagnosed, transplant-ineligible multiple myeloma
  • #VisualAbstract: Pretreatment with radiotherapy and two cycles of concurrent cisplatin may reduce toxicity in locally advanced nasopharyngeal carcinoma
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.